H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)
H.C. Wainwright's Douglas Tsao maintains a Hold rating on Outlook Therapeutics with a $1.00 price target. Tsao, a 5-star analyst with a 22% average return, focuses on healthcare stocks. The consensus rating for Outlook Therapeutics is Hold, with an average price target of $4.00.
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Outlook Therapeutics, with a price target of $1.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Tsao is a 5-star analyst with an average return of 22.0% and a 53.85% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes.
Currently, the analyst consensus on Outlook Therapeutics is a Hold with an average price target of $4.00.
